Loading company
TAKTakeda Pharmaceutical Company Limited$34.4BABuilt from Inmed Pharmaceuticals Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
The themes Inmed Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
INM · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$15.56+17.8%Nov 6 close
Reported results on November 10, 2026; they are not in these figures yet.
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Grade F-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 17 quarters of Inmed Pharmaceuticals Inc.’s grade history. The other 15 go back to September 2022.
